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SECTION	2:	INTRODUCTION	
Objective	
The	Chronic	Headache	Education	and	Self-management	Study	(CHESS)	is	a	multicomponent	
programme	of	interlocking	studies	funded	by	an		NIHR	programme	grant	to	develop	an	
education	and	self-management	support	intervention	for	people	living	with	chronic	
headache	(here	in	referred	to	as	the	CHESS	intervention)	and	assess	its	clinical	and	cost-
effectiveness	in	a	randomised	controlled	trial.		This	analysis	plan	relates	to	the	economic	
evaluation	of	the	CHESS	intervention	using	data	from	the	two-arm	multi-centre	randomised	
controlled	trial	component	of	the	CHESS	programme.		The	within-trial	economic	evaluation	
will	aim	to	estimate	the	cost-effectiveness	of	the	CHESS	intervention	compared	with	best	
supportive	care	over	the	12-month	trial	period	of	follow-up.	The	purpose	of	the	health	
economics	analysis	plan	is	to	outline	an	explicit	framework	of	methods	that	will	be	used	to	
analyse	the	health	economic	data	in	a	robust	manner.	The	document	has	been	written	
based	on	information	contained	in	the	trial	protocol	version	3.7	dated	on	19.Sep.2019.		
Background	rationale	
Chronic	headaches	present	a	major	problem	both	for	the	individual	and	society.	Previous	
studies	on	supportive	self-management	interventions	in	this	population	have	largely	been	
small	studies	with	short	term	follow-up,	they	often	did	not	report	clinically	relevant	
outcomes,	or	were	conducted	in	different	healthcare	systems	therefore	difficult	to	translate	
into	an	NHS	setting.	These	studies	also	did	not	necessarily	focus	on	chronic	headache	but	
rather	looked	at	headache	with	no	frequency	specified.	Based	on	the	results	of	our	
systematic	review	there	may	be	potential	for	large	gain	through	a	combination	of	self-
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management	education	and	appropriate	use	of	prophylaxis	and	management	of	medication	
overuse	headache	in	a	chronic	headache	population.	
	
In	order	to	develop	the	evidence	base	needed	for	self-management	intervention	for	chronic	
headache	there	needs	to	be	a	carefully	developed,	piloted	and	evaluated	intervention	
package	which	has	been	supported	by	good	qualitative	work	on	understanding	outcomes	of	
interest.	There	is	therefore	the	need	for	a	robust	clinical	and	cost-effectiveness	trial	within	
an	NHS	setting.	
	
Objectives	
The	objective	is	to	answer	the	question:	Amongst	adults	with	chronic	headache	arising	from	
migraine,	chronic	tension	type	headache	or	medication	overuse	headache,	is	the	provision	
of	a	self-management	support	programme	in	addition	to	best	usual	NHS	care	clinically	and	
cost	effective?	
SECTION	THREE:	METHODS	
General	principles	for	economic	evaluation	
The	within-trial	economic	analysis	will	be	conducted	under	the	intention	to	treat	(ITT)	
principle.	This	requires	that	study	participants		are	analysed	according	to	their	treatment	
assignment	regardless	of	actual	treatment	received	(1).	The	perspective	of	the	base	case	
analysis	will	be	that	of	the	UK	National	Health	Service	and	Personal	Social	Services	
(NHS/PSS),	the	recommended	perspective	for	technology	appraisals	in	the	National	Institute	
for	Health	and	Care	Excellence	(NICE)	reference	case	(2).	Secondary	analyses	will	consider	
costs	from	a	wider	societal	perspective	(3).	A	12-month	time	horizon	will	be	adopted	for	the	
within-trial	analysis	to	mirror	the	trial	follow-up	period	and	therefore	costs	and	outcomes	
will	not	be	discounted	due	to	this	shorter	time	horizon.	However,	we	will	develop	a	decision	
analytic	model	to	extrapolate	trial	results	beyond	the	trial	follow-up	and	assess	the	long-
term	cost-effectiveness	of	the	CHESS	intervention.		Costs	and	outcomes	in	the	decision	
model	will	be	discounted	at	3.5%	beyond	the	first	year	post	randomisation	in	accordance	
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with	the	NICE	reference	case	(2).	Findings	will	be	reported	in	accordance	with	the	
Consolidated	Health	Economic	Evaluation	Reporting	Standards	(CHEERS)	statement	for	the	
reporting	of	health	economic	evaluations	(4).	
Resource	use	and	costs	
Health	and	social	care	resource	use	will	be	collected	for	each	trial	participant	over	the	12-
month	period	of	follow-up.	As	outlined	in	the	study	protocol,	the	CHESS	intervention	
consists	of	i)	a	structured	education	and	self-management	sessions	delivered	to	groups	of	
10-12	patients	over	two	days,	ii)	one-to-one	consultation	with	the		group	facilitator	(usually	
a	registered	nurse)		for	each	participant	and	iii)		a	follow-on	telephone	call	within	the	first	8	
weeks	of	participating	in	the	group	session.	Each	interventional	group	will	be	facilitated	by	a	
trained	registered	nurse	(grade	5	and	above)	and	one	allied	health	professional.	Resource	
use	and	costs	associated	with	delivery	of	the	intervention	will	be	estimated	based	on:	(i)	a	
detailed	record	of	each	group	activity	including	the	number	of	patients	attending	each	
group,	duration	of	sessions,	number	of	staff	facilitators	and	their	respective	grades	and	set-
up	costs	such	as		administrative	support,	educational	material/leaflets	and	the	
room/facilities	where	the	group	activities	takes	place,	(ii)	number	and	length	of	one-to-one	
consultations	with	the	clinical	nurse	and	(iii)	number	and	length	of	telephone	follow-up	
consultations	and	the	clinical	grade	of	the	staff	conducting	the	consultation.	Participants	in	
the	control	group	will	be	provided	with	a	relaxation	CD,	the	unit	cost	of	which	will	be	
calculated	based	on	the	procurement	costs	for	use	of	the	CD	in	the	trial.		
In	addition	to	the	resource	use	associated	with	delivery	of	the	interventions,	resource	
utilisation	data	covering	the	4-month	period	prior	to	randomisation	(to	establish	baseline	
estimates)	and	the	12-month	post-randomisation	period	will	be	collected	for	each	trial	
participant	through	two	principal	means:	(i)	the	trial	case	report	forms	including	relevant	
primary/community	care	service	use	and	hospital	inpatient	admissions	and	outpatient	
attendances		and	(ii)	the	computerised	electronic	record	systems	of	participating	general	
practice	(GP)	surgeries.	Primary	care,	hospital	inpatient	and	outpatient	resource	utilisation	
will	be	extracted	from	these	sources	for	each	trial	participant.	Primary	care	utilisation	will	be	
extracted	from	the	electronic	general	practice	records,	which	include	details	of	
consultations	i.e.	the	number	and	type	of	consultations	for	example	with	a	GP,	practice	
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nurse	or	other	community	based	health	and	social	care	professional	or	service	and	
prescriptions.		Secondary	care	utilisation	data	to	be	extracted	from	the	GP	electronic	health	
records	will	include	details	of	hospital	day	case	and	inpatient	admissions	(referral	method	
and	type	of	admission,	type	of	ward,	length	of	stay	and	details	of	diagnosis	and	procedures	
undertaken)	and	details	of	outpatient	attendances	(for	example,	headache	clinic/neurology	
clinics,	physiotherapy	clinics,	accident	and	emergency,	medical	tests,	scans	and	
investigations).	Economic	questionnaires	completed	by	study	participants	at	4,	8	and	12	
month	assessment	will	provide	additional	secondary	sources	of	NHS	and	Personal	social	
service	utilisation	(community	health	and	social	care	encounters	and	utilisation	of	hospital-
based	services).	Costs	based	on	resource	use	extracted	from	the	GP	records	will	act	as	the	
primary	source	of	cost	data	for	the	economic	evaluation.	Costs	estimated	from	resource	use	
collected	through	the	patient	reported	questionnaires	will	act	as	secondary	data	sources	
and	will	only	be	used	where	no	equivalent	cost	information	is	available	from	the	GP	records.	
Private	healthcare	utilisation	(including	over	the	counter	medication	use),	out-of-pocket	
expenses	and	travel	costs	borne	by	participants	and	their	relatives,	time-off	work	due	to	
illness,	lost	income	and	use	of	community	social	care	services	such	as	meals	on	wheels	
(although	use	of	these	would	most	likely	be	minimal	for	the	CHESS	trial	population).	These	
will	be	measured	using	the	economic	questionnaires	completed	by	study	participants	at	4,	8	
and	12	month	assessment.	Private	healthcare	costs	will	be	categorised	into	costs	borne	by	
other	sector	of	the	economy,	e.g.	use	of	community	social	care	services,	and	cost	borne	by	
individuals.	
Current	UK	unit	costs	will	be	applied	to	each	resource	item	to	value	total	resource	use	in	
each	arm	of	the	trial.	A	per	diem	cost	for	each	level	of	hospital	care,	delineated	by	level	of	
intensity,	will	be	calculated	using	national	tariffs.	The	unit	costs	of	community	health	and	
social	services	will	largely	be	derived	from	latest	Unit	Costs	of	Health	and	Social	Care	2018	
report	published	by	the	Personal	Social	Services	Research	Unit	(PSSRU)(5),	supplemented	by	
information	obtained	from	published	literature	and	online	sources.		The	primary	analysis	
will	concentrate	on	direct	intervention	and	broader	healthcare/PSS	costs,	whilst	wider	
impact	(societal)	costs	will	be	included	within	one	of	the	sensitivity	analyses.	
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Outcomes	
The	primary	outcome	of	the	within-trial	economic	evaluation	will	be	the	quality-adjusted	life	
year	(QALY)	as	recommended	in	the	NICE	reference	case	(2).	This	will	allow	incremental	
cost-effectiveness	ratios	for	CHESS	intervention	compared	with	best	usual	care	to	be	
generated	in	the	form	of	incremental	cost	per	QALY	gained.	The	QALY	is	a	measure	that	
combines	quantity	and	quality	of	life	lived	into	a	single	metric,	with	one	QALY	notionally	
equating	to	one	year	of	full	health.	QALY	estimates	are	generated	from	combining	length	
and	health-related	quality	of	life	outcomes	using	area-under-the-curve	approaches	(6).	This	
requires	survival	and	health-related	quality	of	life	data	from	or	on	behalf	of	trial	participants	
for	the	period	covering	the	trial	time	horizon.	Health-related	quality	of	life	collected	for	trial	
participants	(see	details	below)	will	be	converted	into	health-state	utilities	indexed	at	0	and	
1	where	0	represents	death	and	1	represents	full	health.	
Participants	will	be	asked	to	complete	the	EuroQoL	EQ-5D-5L	(7)	and	SF-12	(8)	measures	
using	postal	questionnaire	at	baseline	and	during	follow-up	at	the	4,	8	and	12	months	post-
randomisation	assessment	points.		Responses	to	the	EQ-5D	and	SF-12	will	be	converted	into	
multi-attribute	utility	scores	using	established	algorithms	(9,	10)	from	which	QALYs	can	be	
generated.	The	EQ-5D	is	a	generic	preference	based	5-dimensional	multi-attribute	
instrument	for	measuring	health-related	quality	of	life.	Currently,	there	are	two	versions	of	
the	questionnaire:	a	3-level	version	(EQ-5D-3L)	first	introduced	in	1990	by	the	EuroQoL	
Group	(11)	and	a	newer	5-level	version	(EQ-5D-5L)	introduced	in	2009	(12).	Patients	in	the	
CHESS	trial	will	complete	the	5L	version	of	the	questionnaire.	The	5L	responses	can	be	
converted	into	health	utilities	using	a	recently	published	value	set	for	England	(13).	
However,	since	publication	of	the	EQ-5D-5L	value	set,	NICE	has	released	a	position	
statement	(14)	advising	against	the	use	of	the	new	tariff	(13)	until	the	outcome	of	ongoing	
research	exploring	the	impact	of	adopting	the	EQ-5D-5L	valuation	set	in	the	NICE	reference	
case	becomes	available.	The	position	statement	further	recommends	that	during	this	
interim	period,	EQ-5D-5L	responses	should	be	mapped	or	cross-walked	onto	the	EQ-5D-3L	
using	the	Hout	et	al.	(15)	algorithm	and	the	health	utilities	then	derived	from	EQ-5D-3L	
utility	scores	using	the	UK	value	set	for	the	EQ-5D-3L	(16).	Therefore,	we	initially	plan	to	use	
the	utility	values	derived	from	cross-walking	the	EQ-5D-5L	responses	onto	the	EQ-5D-3L	
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using	the	Hout	et	al.	method	to	generate	QALYs	for	the	base	case	analysis.	Sensitivity	
analyses	will	s	will	be	conducted	using	health	utility	values	generated	from	the	SF-12	using	
the	algorithm	of	Brazier	et	al	(17).		
SECTION	FOUR:	Mapping	sub-study	
A	separate	sub-study	will	be	conducted	as	part	of	the	CHESS	programme	of	research	to	
develop	methods	for	mapping	or	cross-walking	two	headache-specific	questionnaires	(the	6-
item	Headache	Impact	Test	(HIT-6)	and	the	Chronic	Headache	Quality	of	Life	Questionnaire	
(CHQLQ	v1)	onto	generic	health	related	quality	of	life	questionnaires	(the	EQ-5D-5L	and	the	
SF-12	v2).	A	cross-sectional	sample	(sample	size:	400-500)	of	people	living	with	chronic	
headaches	will	be	recruited	from	among	patients	attending	headache	clinics	within	NHS	
hospital	outpatient	departments	for	the	mapping	study.	The	headache-specific	
questionnaires	are	more	likely	to	be	responsive	to	improvement	or	worsening	in	headache-
related	symptoms	than	generic	health-related	quality	of	life	measures	such	as	the	EQ-5D-5L	
and	SF-12.	Utilities	based	on	the	EQ-5D-5L	or	the	SF-6D	(via	SF-12)	can	then	be	derived	from	
the	mapping	algorithms.	We	will	use	utilities	generated	from	the	HIT-6	and	the	CHQLQ	via	
the	mapping	functions	as	an	alternative	source	of	health	utility	in	the	base-case	analysis	
where	data	from	the	EQ-5D-5L	and	the	SF-12	v2	are	missing.		We	will	also	use	them	stand	
alone	sensitivity	analyses	to	explore	the	robustness	of	the	cost-effectiveness	results	to	
different	approaches	to	measuring	health-related	quality	of	life	impact	of	intervention.		
SECTION	FIVE:	DATA	
Data	quality	and	cleaning	
All	data	relevant	to	the	health	economics	analysis	will	be	examined	for	data	quality.	
Questionnaires	will	be	checked	for	completeness	on	return	to	the	trial	office.	Any	
questionable	data	will	be	queried	with	trial	staff	and	inappropriate	or	unclear	responses	will	
be	handled	in	accordance	with	pre-specified	data	entry	guidance.	Unresolved	issues	after	
referral	to	the	data	entry	instructions	will	be	discussed	with	the	trial	health	economists	and	
clarification	sought	from	the	clinical	team	if	necessary.	Agreed	line	of	actions	for	addressing	
data	quality	issues	will	be	documented	in	the	data	entry	guidance	documentation.			
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Missing	data	
Any	missing	items	present	after	the	data	cleaning	stage	will	be	addressed	within	the	health	
economic	analysis	strategy	as	missing	data.	Missing	data	is	a	common	occurrence	within	
trial-based	economic	evaluations	and	it	is	necessary	to	address	it	in	a	standardised	
principled	manner.	Within	the	health	economic	literature,	trial-based	economic	evaluations	
have	been	subject	to	particular	criticism	for	failing	to	use	appropriate	methods	to	address	
missing	data	(18).	Descriptive	analyses	of	missing	data	will	be	carried	out	(missing	data	
patterns	using	graphical	tools,	association	between	missing	data	and	baseline	variables,	
association	between	missing	data	and	outcomes).	The	results	of	the	descriptive	analysis	will	
be	discussed	by	the	trial	team	to	infer	possible	reasons	for	missing	data	and	inform	the	
assumption	about	the	missing	data	mechanism.	In	line	with	best	practice	recommendations	
for	analysis	of	within-trial	economic	data	(19),	multiple	imputation	by	chain	equations	
implemented	through	the	MICE	package	(20)	in	statistical	package	R	version	3.13	(21)		will	
be	used	to	handle	missing	data	for	each	assessment	point	(baseline,	4-,	8-	and	12-month	
follow-up).	Multiple	imputation	(MI)	generates	a	series	of	datasets	with	each	dataset	
replacing	missing	values	with	sampled	values.	MI	replaces	each	missing	observation	with	a	
set	of	plausible	imputed	values,	taken	from	the	predictive	distribution	of	the	missing	data	
given	the	observed	data	(22).	Such	methods	can	handle	data	assumed	missing	at	random	
(MAR)	and	can	be	modified	to	handle	data	assumed	missing	not	at	random	(MNAR)	(23).	
Appropriateness	of	the	MAR	assumption	will	be	assessed	by	comparing	the	characteristics	
of	patients	with	and	without	missing	data	at	each	follow-up	time	point.	Imputated	data	will	
be	generated	separately	by	treatment	group	as	recommended	by	Faria	et	al	(24)	using	the	
predictive	mean	matching	method	which	has	the	advantage	of	preserving	non-linear	
relationships	and	correlations	between	variables	within	the	data.	Estimates	obtained	will	be	
pooled	to	generate	mean	and	variance	estimates	of	costs	and	QALYs	using	Rubin’s	rule	in	
order	to	capture	within	and	between	variances	for	imputed	samples.	We	will	fit	models	
under	a	missing	not	at	random	(NMAR)	assumption	by	systematically	varying	values	of	
imputed	costs	and	utilities	from	0	to	±100%	within	the	imputation	models	to	assess	the	
robustness	of	our	base-case	results	to	the	missing	at	random	assumption.	
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SECTION	SIX:	ANALYSIS		
Summary	of	resource	use	and	costs	
Patient-level	costs	will	be	generated	for	each	resource	variable	by	multiplying	the	quantity	
reported	with	the	respective	unit	cost,	weighted	by	length	of	stay	or	duration	of	contact	
where	appropriate.	Summary	statistics	(means,	standard	errors	and	completion	rates)	will	
be	generated	by	treatment	allocation	and	assessment	point.	Between	treatment-group	
differences	in	mean	resource	use	and	mean	costs	at	each	assessment	point	will	be	
compared	using	the	two-sample	t-test.	Statistical	significance	was	assessed	at	the	5%	
significance	level.	A	non-parametric	bootstrap	routine	with	bias	correction	for	standard	
errors	and	confidence	intervals	will	be	implemented,	generating	1,000	replications	of	the	
data.	Estimates	of	standard	errors	surrounding	mean	resource	use	(or	cost)	estimates	and	
95%	confidence	intervals	surrounding	between-group	differences	in	mean	resource	use	(or	
costs)	will	be	obtained	from	the	bootstrap	samples.	
	
Cost-effectiveness	analysis	
Cost-effectiveness	results	for	the	base	case	analysis	will	be	obtained	by	formulating	a	
system	of	seemingly	unrelated	mixed-effects	regressions	for	individual-level	costs	and	
effects,	accounting	for	the	patient-level	correlations	between	the	two	and	adjusting	for	pre-
specified	baseline	patient	characteristics.	The	covariates	to	be	included	in	the	regressions	
will	be	those	selected	a	priori	for	the	adjusted	statistical	analysis,	namely	age,	gender	and	
the	baseline	stratification	factors	(type	of	headache	and	geographical	locality).	The	group	
sessions	to	which	patients	in	the	intervention	as	clustering	variable	in	the	intervention	
group	and	the	control	group	will	act	as	a	separate	cluster	on	its	own.		Additionally,	we	will	
control	for	imbalance	in	baseline	costs	and	EQ-5D	values	between	the	two	trial	arms	by	
including	a	covariate	for	baseline	costs	in	the	cost	model	and	baseline	health	related	quality	
of	life	in	the	QALY	model,	a	practice	that	is	now	standard	for	trial-based	economic	
evaluations	(25).	Estimates	of	the	incremental	costs	and	QALYs	associated	with	the	CHESS	
intervention	compared	with	best	usual	care	will	be	generated	from	the	regressions	and	
presented	as	incremental	cost-effectiveness	ratios	(ICERs)	and	cost-effectiveness	
acceptability	curves	(CEACs).	This	accommodates	sampling	(or	stochastic)	uncertainty	and	
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varying	levels	of	willingness	to	pay	for	an	additional	QALY	such	as		£15,000	per	QALY	
threshold	recently	estimated	by	Claxton	et	al.	(26)	and	the	£20,000	to	£30,000	per	QALY	
threshold	used	by	NICE	in	its	technology	appraisal	process.(27)	Heterogeneity	in	the	trial	
population	will	be	explored	by	formulating	a	net-benefit	value	for	each	patient	from	the	
observed	costs	and	effects,	and	then	constructing	a	regression	model	with	a	treatment	
variable	and	covariates	such	as	age,	gender,		medication	overuse	and	headache	type	where	
data	allows	us	to	do	so.		Treatment	by	covariate	interaction	terms	will	be	included	for	each	
covariate	one	at	a	time.	The	magnitude	and	significance	of	the	coefficients	on	the	
interaction	between	the	covariates	and	the	treatment	variable	should	provide	an	estimate	
of	the	cost-effectiveness	of	the	intervention	by	sub-group.	
Additionally,	due	to	known	limitations	of	within-trial	economic	evaluations(28),	we	will	also	
construct	a	Cohort	Markov	model	to	model	beyond	the	parameters	of	the	proposed	within-
trial	cost-effectiveness	of	the	intervention	in	the	relevant	patient	population.	We	will	inform	
the	model	with	data	from	the	trial	as	well	as	information	identified	from	our	systematic	
search	of	the	literature.		Long	term	estimates	of	costs	and	health	consequences	will	be	
discounted	to	present	values	using	discount	rates	recommended	for	health	technology	
appraisal	in	the	United	Kingdom.	A	series	of	probabilistic	sensitivity	analyses	will	be	
undertaken	to	explore	the	implications	of	parameter	uncertainty	on	the	incremental	cost-
effectiveness	ratios.	All	analyses	will	be	conducted	using	the	statistical	package	R	(21).	
	
Sensitivity	analyses	
The	following	sensitivity	analyses	will	be	conducted	to	investigate	sensitivity	of	the	base	
case	results	to:	
• Utilities	generated	from	via	the	SF-12/SF-6D	tariff	for	UK	(17)	
• The	new	EQ-5D-5L	tariff	for	England	(29)	
• Costs	calculated	from	a	societal	perspective	
• Complete	case	analysis	as	the	base	case	cost-effectiveness	analysis	uses	imputed	
attributable	costs	and	QALYs.	
• EQ-5D-5L	utilities	derived	HIT-6	via	mapping	coefficients	
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• EQ-5D-5L	utilities	derived	CHQLQ	via	mapping	coefficients	
• SF-6D	utilities	derived	HIT-6	via	mapping	coefficients	
• SF-6D	utilities	derived	CHQLQ	via	mapping	coefficients	
Subgroup	analyses	
Estimates	of	incremental	cost-effectiveness	will	be	calculated	for	the	following	subgroup	of	
patients.		
• Medication	overuse	
o Yes	
o No	
• Location	(Midlands	versus	Greater	London)	
• Gender	(Female	versus	Male)	
• Age	group	(<40years	versus	≥40	years)	
	
SECTION	SEVEN:	TEMPLATE	TABLES	AND	FIGURES	
Results	Tables	
Table	1:	Completion	rates	for	health	economic	outcomes	
	 Completion	rates	
Assessment	point	and	resource	category	 CHESS	
intervention	
(n=xxx)	
Best	usual	
care	
(n=xxx)	
Baseline	 	 	
EQ-5D-5L	index	 xxx%	 xxx%	
EQ-5D-5L	VAS	 xxx%	 xxx%	
SF-12	(SF-6D)	utility	score	 xxx%	 xxx%	
Hospital	inpatient	(admitted	care)	 xxx%	 xxx%	
Day	case	attendance	 xxx%	 xxx%	
Outpatient	attendance		 xxx%	 xxx%	
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Consultations	(primary	care)	–	does	this	need	to	be	split	by	type	ie	
GP,	nurse	
xxx%	 xxx%	
Tests	and	investigations	(primary	care)	 xxx%	 xxx%	
Prescribed	medication	(primary	care)	 	 	
Over	the	counter	medication		 xxx%	 xxx%	
Private	healthcare	expenditure	 xxx%	 xxx%	
Additional	costs	 xxx%	 xxx%	
Lost	income	due	to	headache	related	illness	 xxx%	 xxx%	
Time	off	work	due	to	headache	related	illness	 xxx%	 xxx%	
4	month	assessment	point	 	 	
8	month	assessment	point	 	 	
12	month	assessment	point	 	 	
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Table	2:	Health	and	social	care	resource	utilisation	during	follow-up	
	 	 CHESS	intervention	(n=xxxx)	 Best	usual	care	(n=xxxx)	 CHESS	intervention	versus	
best	usual	care	
Assessment	
point	
Category		 %	
missing	
Number	
of	visits,	
mean	
(se)	
Total	duration	
in		days	/	
minutes,	mean	
(se)	
%	
missing	
Number	
of	visits,	
mean	
(se)	
Total	duration	
in		
days/minutes,	
mean	(se)	
Total	duration,	
mean	difference	
(bootstrap	95%	CI)1	
P-value	
	
Baseline	 Hospital	inpatient	 	 	 	 	 	 	 	 	
Day	case	 	 	 	 	 	 	 	 	
Admitted	care	(overnight	
stay)	
	 	 	 	 	 	 	 	
Hospital	outpatient	 	 	 	 	 	 	 	 	
Headache	clinic	 	 	 	 	 	 	 	 	
Physiotherapist	 	 	 	 	 	 	 	 	
Occupational	therapist	 	 	 	 	 	 	 	 	
Radiology:	MRI	scan	 	 	 	 	 	 	 	 	
Radiology:	CT	scan	 	 	 	 	 	 	 	 	
Radiology:	X-ray	 	 	 	 	 	 	 	 	
Radiology:	Ultrasound	 	 	 	 	 	 	 	 	
Blood	tests2	 	 	 	 	 	 	 	 	
Accident	and	emergency	 	 	 	 	 	 	 	 	
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Other	outpatient			 	 	 	 	 	 	 	 	
Primary	care		 	 	 	 	 	 	 	 	
GP,	surgery	visit	 	 	 	 	 	 	 	 	
GP,	home	visit	 	 	 	 	 	 	 	 	
GP,	telephone	contact	 	 	 	 	 	 	 	 	
Practice	nurse	 	 	 	 	 	 	 	 	
District	nurse	 	 	 	 	 	 	 	 	
Community	
physiotherapist	
	 	 	 	 	 	 	 	
Occupational	therapist	 	 	 	 	 	 	 	 	
counsellor	 	 	 	 	 	 	 	 	
Psychology/psychotherapy	 	 	 	 	 	 	 	 	
Social	worker	 	 	 	 	 	 	 	 	
Any	other	contact	 	 	 	 	 	 	 	 	
4	month	
assessment	
point	
	 	 	 	 	 	 	 	 	
8	month	
assessment	
point	
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12	month	
assessment	
point	
	 	 	 	 	 	 	 	 	
1mean	difference	and	95%	bias	corrected	bootstrap	confidence	intervals	
	
Table	3:	Health	and	social	care	costs	incurred	during	trial	follow-up	
	 	 CHESS	intervention	(n=xxxx)	 Best	usual	care	(n=xxxx)	 CHESS	intervention	versus	
best	usual	care	
Assessment	
point	
Category		 %	
missing	
%	zero	
costs	
Mean	costs	
(se)	
%	
missing	
%	zero	
costs	
Mean	costs	
(se)	
Mean	difference,	
(bootstrap	95%	CI)1	
P-
value	
Baseline		 Hospital	inpatient	 	 	 	 	 	 	 	 	
Day	case	 	 	 	 	 	 	 	 	
Admitted	care	(overnight	stay)	 	 	 	 	 	 	 	 	
Total	inpatient	costs	 	 	 	 	 	 	 	 	
Hospital	outpatient	 	 	 	 	 	 	 	 	
Headache	clinic	 	 	 	 	 	 	 	 	
Physiotherapist	 	 	 	 	 	 	 	 	
Occupational	therapist	 	 	 	 	 	 	 	 	
Radiology:	MRI	scan	 	 	 	 	 	 	 	 	
Radiology:	CT	scan	 	 	 	 	 	 	 	 	
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Radiology:	X-ray	 	 	 	 	 	 	 	 	
Radiology:	Ultrasound	 	 	 	 	 	 	 	 	
Accident	and	emergency	 	 	 	 	 	 	 	 	
Other	outpatient			 	 	 	 	 	 	 	 	
Total	outpatient	costs	 	 	 	 	 	 	 	 	
Primary	care		 	 	 	 	 	 	 	 	
	GP,	surgery	visit	 	 	 	 	 	 	 	 	
GP,	home	visit	 	 	 	 	 	 	 	 	
GP,	telephone	contact	 	 	 	 	 	 	 	 	
Practice	nurse	 	 	 	 	 	 	 	 	
District	nurse	 	 	 	 	 	 	 	 	
Community	physiotherapist	 	 	 	 	 	 	 	 	
Occupational	therapist	 	 	 	 	 	 	 	 	
counsellor	 	 	 	 	 	 	 	 	
Psychology/psychotherapy	 	 	 	 	 	 	 	 	
Social	worker	 	 	 	 	 	 	 	 	
Any	other	contact	 	 	 	 	 	 	 	 	
Total	primary	care	costs	 	 	 	 	 	 	 	 	
1mean	difference	and	95%	bias	corrected	bootstrap	confidence	intervals		
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Table	4:	Private	health	care	resource	use	during	follow-up	
	 	 CHESS	intervention(n=xxxx)	 Best	usual	care	(n=xxxx)	 CHESS	intervention	versus	
best	usual	care	
Assessmen
t	point	
Category		 %	
missing	
Number	
of	visits,	
mean	
(se)	
Total	duration	
in		days	/	
minutes,	mean	
(se)	
%	
missing	
Number	
of	visits,	
mean	
(se)	
Total	duration	
in		days	/	
minutes,	mean	
(se)	
Total	duration,	
mean	difference	
(bootstrap	95%	CI)1	
P-
value	
	
Baseline	 Over	the	counter	medication	 	 	 	 	 	 	 	 	
Physiotherapist	 	 	 	 	 	 	 	 	
Occupational	therapist	 	 	 	 	 	 	 	 	
Counsellor	 	 	 	 	 	 	 	 	
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Psychologist	 	 	 	 	 	 	 	 	
Radiology:	MRI	scan	 	 	 	 	 	 	 	 	
Radiology:	CT	scan	 	 	 	 	 	 	 	 	
Radiology:	X-ray	 	 	 	 	 	 	 	 	
Radiology:	Ultrasound	 	 	 	 	 	 	 	 	
Consultant	service	 	 	 	 	 	 	 	 	
Osteopath	 	 	 	 	 	 	 	 	
Chiropractor	 	 	 	 	 	 	 	 	
Acupuncturist		 	 	 	 	 	 	 	 	
Homeopath	 	 	 	 	 	 	 	 	
Other	 	 	 	 	 	 	 	 	
4	month	
assessment	
point	
	 	 	 	 	 	 	 	 	
8	month	
assessment	
point	
	 	 	 	 	 	 	 	 	
12	month	
assessment	
point	
	 	 	 	 	 	 	 	 	
1mean	difference	and	95%	bias	corrected	bootstrap	confidence	intervals	
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Table	5:	Private	healthcare	costs	incurred	during	follow-up	
	 	 CHESS	intervention	(n=xxxx)	 Best	usual	care	(n=xxxx)	 CHESS	intervention	versus	
best	usual	care	
Assessmen
t	point	
Category		 %	
missing	
%	zero	
costs	
Mean	costs	(se)	 %	
missing	
%	zero	
costs	
Mean	costs	(se)	 Mean	cost	
difference,	
(bootstrap	95%	CI)1	
P-
value	
Baseline	 Over	the	counter	medication	 	 	 	 	 	 	 	 	
Physiotherapist	 	 	 	 	 	 	 	 	
Occupational	therapist	 	 	 	 	 	 	 	 	
Counsellor	 	 	 	 	 	 	 	 	
Psychologist	 	 	 	 	 	 	 	 	
Radiology:	MRI	scan	 	 	 	 	 	 	 	 	
Radiology:	CT	scan	 	 	 	 	 	 	 	 	
Radiology:	X-ray	 	 	 	 	 	 	 	 	
Radiology:	Ultrasound	 	 	 	 	 	 	 	 	
Consultant	service	 	 	 	 	 	 	 	 	
Osteopath	 	 	 	 	 	 	 	 	
Chiropractor	 	 	 	 	 	 	 	 	
Acupuncturist		 	 	 	 	 	 	 	 	
Homeopath	 	 	 	 	 	 	 	 	
	22	
CHESS	Health	Economics	Analysis	Plan_V2.0_27.Nov.2019	
IRAS:	215304	
	
Other	 	 	 	 	 	 	 	 	
Total	baseline	costs	 	 	 	 	 	 	 	 	
4	month	
assessment	
point	
	 	 	 	 	 	 	 	 	
8	month	
assessment	
point	
	 	 	 	 	 	 	 	 	
12	month	
assessment	
point	
	 	 	 	 	 	 	 	 	
1mean	difference	and	95%	bias	corrected	bootstrap	confidence	intervals	
	
Table	6:	Additional	costs	incurred	during	trial	follow-up	
	 	 CHESS	intervention	(n=xxxx)	 Best	usual	care	(n=xxxx)	 CHESS	intervention	versus	
best	usual	care	
Assessment	
point	
Category		 %	
missing	
Number	
of	visits,	
mean	(se)	
Total	number	
of	days,	mean	
(se)	
%	
missing	
Number	
of	visits,	
mean	(se)	
Total	number	
of	days,	mean	
(se)	
Mean	difference,	
(bootstrap	95%	
CI)1	
P-value	
	
3	months	post	
randomisation	
Travel	costs	(e.g.	bus	fares)	 	 	 	 	 	 	 	 	
Child	care	costs	 	 	 	 	 	 	 	 	
Income	lost	 	 	 	 	 	 	 	 	
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Cost	of	help	with	
housework	
	 	 	 	 	 	 	 	
Cost	of	laundry	services	 	 	 	 	 	 	 	 	
Other	additional	costs	 	 	 	 	 	 	 	 	
Total	additional	costs	 	 	 	 	 	 	 	 	
4	month	
assessment	
point	
	
	 	 	 	 	 	 	 	
8	month	
assessment	
point	
	
	 	 	 	 	 	 	 	
12	month	
assessment	
point	
	
	 	 	 	 	 	 	 	
1mean	difference	and	95%	bias	corrected	bootstrap	confidence	intervals	for	total	number	of	days	or	number	of	contacts/visits	when	number	of	days	is	not	relevant	
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Table	7:	Sources	of	unit	costs	information	
Category	 Currency	code	 Unit	
cost	
Source	
Inpatients	(per	day	
of	inpatient	stay)	
		 		 		
Day	case	 	 	 	
Admitted	care	 	 	
Accident	and	
emergency	
	 	
Out	patients	(per	
contact)	
	 	 	
General	surgery	 	 	 	
ENT	 	 	
Accident	and	
Emergency	
	 	
Pain	clinic	 	 	
General	Medicine	 	 	
Diabetes	 	 	
Cardiology	 	 	
Dermatology	 	 	
Breast	clinic	 	 	
Neurology	 	 	
Rheumatology	 	 	
Dentist	 	 	
Eye	Clinic	 	 	
Gynaecology	 	 	
Midwife	 	 	
Osteopath	 	 	
Physiotherapy	 	 	
Chiropractor	 	 	
Podiatrist	 	 	
Mental	health	 	 	
Blood	test	 	 	
Occupational	health	 	 	
MRI	Scan	 	 	
CT	Scan	 	 	
X-Ray	scan	 	 	
Primary	and	social	
care	(cost	per	
contact)	
	 	 	
Acupuncture	 	 	 	
Chiropractor	 	 	
Physiotherapy	 	 	
Osteopathy	 	 	
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Massage	 	 	
Pharmacist	 	 	
Psychology	 	 	
Counsellor	 	 	 	
District	nurse/	
health	visitor	/	
midwife	
	 	 	
Practice	nurse	 	 	 	
GP	home	visit	 	 	 	
GP	surgery	 	 	 	
GP	telephone	 	 	
Health	care	assistant	 	 	 	
Private	costs	 	 	 	
Physiotherapy	 	 	 	
Psychology	 	 	 		
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Table	8:	Total	economic	costs	
	
Costing	perspective	and	list	
of	included	cost	categories	
CHESS	intervention	(n=xxxx)	 	 Best	usual	care	(n=xxxx)	 	 CHESS	intervention	versus	best	usual	
care	
%	
missing	
%	zero	
costs	
Mean	(SE),	£	 	 %	
missing	
%	zero	
costs	
Mean	(SE),	£	 	 Mean	difference	
(bootstrap	95%	CI),	£	
P-value	
	
NHS/PSS	perspective	
	 	 	 	 	 	 	 	 	 	
Intervention	costs	 	 	 	 	 	 	 	 	 	 	
Follow-up	costs	 	 	 	 	 	 	 	 	 	 	
Total	NHS/PSS	costs	 	 	 	 	 	 	 	 	 	 	
	
Societal	perspective	
	 	 	 	 	 	 	 	 	 	
Intervention	costs	 	 	 	 	 	 	 	 	 	 	
Follow-up	costs	(NHS/PSS)	 	 	 	 	 	 	 	 	 	 	
Follow-up	costs	(non-
NHS/PSS)	
	 	 	 	 	 	 	 	 	 	
Total	societal	costs	 	 	 	 	 	 	 	 	 	 	
1Confidence	intervals	obtained	by	bootstrap	bias	corrected	percentile	method	
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Table	9:	Summary	of	EQ5D-5L	responses	and	scores	on	the	visual	analogue	(VAS)	scale	
	 EQ-5D	dimension/	response	 CHESS	
intervention	
(n=xxxx)	
Best	usual	
care	(n=xxxx)	
p-value1	
Baseline	 Mobility	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	walk	 	 	 	
Missing	 	 	 	
Self-care	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	wash/dress	 	 	 	
Missing	 	 	 	
Usual	activities	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	do	usual	activities	 	 	 	
Missing	 	 	 	
Pain	and	discomfort	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Extreme	pain	and	discomfort	 	 	 	
Missing	 	 	 	
Anxiety	and	depression	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Extremely	anxious/depressed	 	 	 	
Missing	 	 	 	
Visual	analogue	score	 	 	 	
Mean	score	(SE)	 	 	 	
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Missing		 	 	 	
4	months	
assessment	
point	
Mobility		 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	walk	 	 	 	
Missing	 	 	 	
Self-care		 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	wash/dress	 	 	 	
Missing	 	 	 	
Usual	activities		 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	do	usual	activities	 	 	 	
Missing	 	 	 	
Pain	and	discomfort	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Extreme	pain	and	discomfort	 	 	 	
Missing	 	 	 	
Anxiety	and	depression	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Extremely	anxious/depressed	 	 	 	
Missing	 	 	 	
Visual	analogue	score	 	 	 	
Mean	score	(SE)	 	 	 	
Missing		 	 	 	
8	months	
assessment	
point	
	
Mobility	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
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Severe	problems	 	 	 	
Unable	to	walk	 	 	 	
Missing	 	 	 	
Self-care	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	wash/dress	 	 	 	
Missing	 	 	 	
Usual	activities	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	do	usual	activities	 	 	 	
Missing	 	 	 	
Pain	and	discomfort	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Extreme	pain	and	discomfort	 	 	 	
Missing	 	 	 	
Anxiety	and	depression	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Extremely	anxious/depressed	 	 	 	
Missing	 	 	 	
Mobility	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	walk	 	 	 	
Missing	 	 	 	
Visual	analogue	score	 	 	 	
Mean	score	(SE)	 	 	 	
Missing		 	 	 	
12	months	
assessment	
point	
Self-care	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
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Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	wash/dress	 	 	 	
Missing	 	 	 	
Usual	activities	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Unable	to	do	usual	activities	 	 	 	
Missing	 	 	 	
Pain	and	discomfort	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Extreme	pain	and	discomfort	 	 	 	
Missing	 	 	 	
Anxiety	and	depression	 	 	 	
No	problems	 	 	 	
Slight	problems	 	 	 	
Moderate	problems	 	 	 	
Severe	problems	 	 	 	
Extremely	anxious/depressed	 	 	 	
Missing	 	 	 	
Visual	analogue	score	 	 	 	
Mean	score	(SE)	 	 	 	
Missing		 	 	 	
1P-values	were	generated	from	chi-squared	tests	for	differences	in	sub-optimal	levels	of	function	for	each	dimension	
where	responses	indicating	no	functional	impairment	were	categorised	as	optimal	and	responses	indicating	any	
functional	impairment	were	categorised	as	sub-optimal.	
	
	
Table	10:	SF-12	v2	responses	
Assessment	point	 Response	 CHESS	
intervention	
(n=xxxx)	
Best	usual	
care	
(N=xxxx)	
P-value1	
Baseline	 General	health	 		 		 	
Excellent	 	 	 	
Very	good	 	 	 	
Good	 	 	 	
Fair	 	 	 	
Poor		 	 	 	
Missing	 	 	 	
Moderate	activities	 	 	 	
Yes,	limited	a	lot	 	 	 	
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Yes,	limited	a	little	 	 	 	
No,	not	limited	at	all	 	 	 	
Missing	 	 	 	
Climbing	stairs	 	 	 	
Yes,	limited	a	lot	 	 	 	
Yes,	limited	a	little	 	 	 	
No,	not	limited	at	all	 	 	 	
Missing	 	 	 	
Accomplished	less	physically	 	 	 	
All	of	the	time	 	 	 	
Most	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Limited	physically	 	 	 	
All	of	the	time	 	 	 	
Most	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Did	less	Work	emotional	 	 	 	
All	of	the	time	 	 	 	
Most	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Accomplished	less	
emotionally	
	 	 	
All	of	the	time	 	 	 	
Most	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Pain	 	 	 	
Not	at	all	 	 	 	
A	little	bit	 	 	 	
Moderately	 	 	 	
Quite	a	bit	 	 	 	
Extremely	 	 	 	
Missing	 	 	 	
Calm	 	 	 	
All	the	time	 	 	 	
Most	of	the	time	 	 	 	
A	good	bit	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	bit	of	the	time	 	 	 	
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None	of	the	time	 	 	 	
Missing	 	 	 	
Energy	 	 	 	
All	of	the	time	 	 	 	
Most	of	the	time	 	 	 	
A	good	bit	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	bit	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Feeling	down	hearted	 	 	 	
All	the	time	 	 	 	
Most	of	the	time	 	 	 	
A	good	bit	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	bit	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Social	activities	 	 	 	
All	the	time	 	 	 	
Most	of	the	time	 	 	 	
A	good	bit	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	bit	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
4	months	post	
randomisation	
General	health	 	 	 	
Excellent	 	 	 	
Very	good	 	 	 	
Good	 	 	 	
Fair	 	 	 	
Poor		 	 	 	
Missing	 	 	 	
Moderate	activities	 	 	 	
Yes,	limited	a	lot	 	 	 	
Yes,	limited	a	little	 	 	 	
No,	not	limited	at	all	 	 	 	
Missing	 	 	 	
Climbing	stairs	 	 	 	
Yes,	limited	a	lot	 	 	 	
Yes,	limited	a	little	 	 	 	
No,	not	limited	at	all	 	 	 	
Missing	 	 	 	
Accomplished	less	physically	 	 	 	
All	of	the	time	 	 	 	
Most	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
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Limited	physically	 	 	 	
All	of	the	time	 	 	 	
Most	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Did	less	Work	emotional	 	 	 	
All	of	the	time	 	 	 	
Most	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Accomplished	less	
emotionally		
	 	 	
All	of	the	time	 	 	 	
Most	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Pain	 	 	 	
Not	at	all	 	 	 	
A	little	bit	 	 	 	
Moderately	 	 	 	
Quite	a	bit	 	 	 	
Extremely	 	 	 	
Missing	 	 	 	
Calm	 	 	 	
All	the	time	 	 	 	
Most	of	the	time	 	 	 	
A	good	bit	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	bit	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Energy	 	 	 	
All	the	time	 	 	 	
Most	of	the	time	 	 	 	
A	good	bit	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	bit	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Feeling	down	hearted	 	 	 	
All	the	time	 	 	 	
Most	of	the	time	 	 	 	
A	good	bit	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
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A	little	bit	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
Social	activities	 	 	 	
All	the	time	 	 	 	
Most	of	the	time	 	 	 	
A	good	bit	of	the	time	 	 	 	
Some	of	the	time	 	 	 	
A	little	bit	of	the	time	 	 	 	
None	of	the	time	 	 	 	
Missing	 	 	 	
8	month	post-	
randomisation	
General	health	 		 		 	
	 Excellent	 	 	 	
	 Very	good	 	 	 	
	 Good	 	 	 	
	 Fair	 	 	 	
	 Poor		 	 	 	
	 Missing	 	 	 	
	 Moderate	activities	 	 	 	
	 Yes,	limited	a	lot	 	 	 	
	 Yes,	limited	a	little	 	 	 	
	 No,	not	limited	at	all	 	 	 	
	 Missing	 	 	 	
	 Climbing	stairs	 	 	 	
	 Yes,	limited	a	lot	 	 	 	
	 Yes,	limited	a	little	 	 	 	
	 No,	not	limited	at	all	 	 	 	
	 Missing	 	 	 	
	 Accomplished	less	physically	 	 	 	
	 All	of	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Limited	physically	 	 	 	
	 All	of	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Did	less	Work	emotional	 	 	 	
	 All	of	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
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	 Accomplished	less	
emotionally	
	 	 	
	 All	of	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Pain	 	 	 	
	 Not	at	all	 	 	 	
	 A	little	bit	 	 	 	
	 Moderately	 	 	 	
	 Quite	a	bit	 	 	 	
	 Extremely	 	 	 	
	 Missing	 	 	 	
	 Calm	 	 	 	
	 All	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 A	good	bit	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	bit	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Energy	 	 	 	
	 All	of	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 A	good	bit	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	bit	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Feeling	down	hearted	 	 	 	
	 All	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 A	good	bit	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	bit	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Social	activities	 	 	 	
	 All	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 A	good	bit	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	bit	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
12	months	post	
randomisation	
General	health	 	 	 	
	 Excellent	 	 	 	
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	 Very	good	 	 	 	
	 Good	 	 	 	
	 Fair	 	 	 	
	 Poor		 	 	 	
	 Missing	 	 	 	
	 Moderate	activities	 	 	 	
	 Yes,	limited	a	lot	 	 	 	
	 Yes,	limited	a	little	 	 	 	
	 No,	not	limited	at	all	 	 	 	
	 Missing	 	 	 	
	 Climbing	stairs	 	 	 	
	 Yes,	limited	a	lot	 	 	 	
	 Yes,	limited	a	little	 	 	 	
	 No,	not	limited	at	all	 	 	 	
	 Missing	 	 	 	
	 Accomplished	less	physically	 	 	 	
	 All	of	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Limited	physically	 	 	 	
	 All	of	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Did	less	Work	emotional	 	 	 	
	 All	of	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Accomplished	less	
emotionally		
	 	 	
	 All	of	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Pain	 	 	 	
	 Not	at	all	 	 	 	
	 A	little	bit	 	 	 	
	 Moderately	 	 	 	
	 Quite	a	bit	 	 	 	
	 Extremely	 	 	 	
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	 Missing	 	 	 	
	 Calm	 	 	 	
	 All	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 A	good	bit	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	bit	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Energy	 	 	 	
	 All	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 A	good	bit	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	bit	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Feeling	down	hearted	 	 	 	
	 All	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 A	good	bit	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	bit	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
	 Social	activities	 	 	 	
	 All	the	time	 	 	 	
	 Most	of	the	time	 	 	 	
	 A	good	bit	of	the	time	 	 	 	
	 Some	of	the	time	 	 	 	
	 A	little	bit	of	the	time	 	 	 	
	 None	of	the	time	 	 	 	
	 Missing	 	 	 	
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Table	11:	Summary	of	health-related	quality	of	life	(utility)	scores	generated	from	EQ-5D-5L	and	SF-12	v2	instruments	
	 CHESS	intervention	 	 Best	usual	care	 	 CHESS	intervention	versus	best	
usual	care	
Outcomes	 N	 %	missing	 Mean	(SE)	 	 N	 %	missing	 Mean	(SE)	 	 Mean	difference	(95%	
CI)	
P-value	
EQ-5D-5L	to	3L	cross	walk1		 	 	 	 	 	 	 	 	 	 	
Baseline	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
4	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
8	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
12	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
EQ-5D-5L	(new	UK	tariff)2	 	 	 	 	 	 	 	 	 	 	
Baseline	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
4	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
8	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
12	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
SF-12	(SF-6D	UK	tariff)	 	 	 	 	 	 	 	 	 	 	
Baseline	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
4	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
8	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
12	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
EQ-5D-5L	VAS	 	 	 	 	 	 	 	 	 	 	
Baseline	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
4	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
8	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
12	months	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
1The	EQ-5D-5L	cross-walk	utility	values	were	derived	using	the	interim	5L	to	3L	cross-walk	tariffs	for	the	UK	(15)		
2New	EQ-5D-5L	value	set	for	England	(13)	
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Table	12:	Unadjusted	estimates	of	Quality-Adjusted	Life	Years	(QALYs)	accrued	over	12	months	of	follow-up	
	 CHESS	intervention	 	 Best	usual	care	plus	relaxation	 	 CHESS	intervention	versus		
best	usual	care	
Outcome	measure	 N	 %	
missing	
Mean	(SE)	 	 N	 %	
missing	
Mean	(SE)	 	 Mean	difference	
(95%	CI)	
P-value	
EQ-5D-5L	cross-walk	tariff	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
EQ-5D-5L	(New	5L	tariff	for	England)	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
SF-12	(SF-6D	tariff)	 xxxx	 	 	 	 xxxx	 	 	 	 	 	
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Table	13:	Cost-effectiveness	of	the	CHESS	intervention	compared	with	best	usual	care	based	on	the	within-trial	economic	analysis	
	 Cost-effectiveness	outcomes	 	 Probability	CHESS	intervention	is	cost-
effective	at	cost-effectiveness	threshold	
of	
Description	 Mean	
incremental	
costs	(95%	CI),	£	
Mean	
incremental	
QALYs	(95%	CI)	
ICER4	 	 £13,000	
per	QALY	
£20,000	
per	QALY	
£30,000	per	
QALY	
Base	case	analysis1	 	 	 	 	 	 	 	
Sensitivity	analyses	 	 	 	 	 	 	 	
		Unadjusted	analysis	 	 	 	 	 	 	 	
		Complete	case	analysis	 	 	 	 	 	 	 	
		Restricted	to	trial	participants	who	did	not	
participate	in	process	evaluation	interviews	
	 	 	 	 	 	 	
		SF-12/SF-6D	 	 	 	 	 	 	 	
		EQ-5D	utilities	derived	HIT-6	via	mapping	
coefficients	
	 	 	 	 	 	 	
		EQ-5D	utilities	derived	CHQLQ	via	mapping	
coefficients	
	 	 	 	 	 	 	
		SF-6D	utilities	derived	HIT-6	via	mapping	
coefficients	
	 	 	 	 	 	 	
		SF-6D	utilities	derived	CHQLQ	via	mapping	
coefficients	
	 	 	 	 	 	 	
Sub-group	analyses	 	 	 	 	 	 	 	
Headache	type	 	 	 	 	 	 	 	
			Chronic	tension	type	headache	 	 	 	 	 	 	 	
			Probable	chronic	migraine	 	 	 	 	 	 	 	
			Definitive	chronic	migraine	 	 	 	 	 	 	 	
Headache	type	with	medication	overuse	 	 	 	 	 	 	 	
			Chronic	tension	type	headache	 	 	 	 	 	 	 	
			Probable	chronic	migraine	 	 	 	 	 	 	 	
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			Definitive	chronic	migraine	 	 	 	 	 	 	 	
Headache	type	without	medication	overuse	 	 	 	 	 	 	 	
			Chronic	tension	type	headache	 	 	 	 	 	 	 	
			Probable	chronic	migraine	without	 	 	 	 	 	 	 	
			Definitive	chronic	migraine	without	 	 	 	 	 	 	 	
Geographical	location	 	 	 	 	 	 	 	
		Midlands	 	 	 	 	 	 	 	
		Greater	London	 	 	 	 	 	 	 	
Sex	 	 	 	 	 	 	 	
			Female	 	 	 	 	 	 	 	
			Male	 	 	 	 	 	 	 	
Age	group	 	 	 	 	 	 	 	
			<40years	 	 	 	 	 	 	 	
			≥40	years	 	 	 	 	 	 	 	
ICER	=	Incremental	cost-effectiveness	ratio;	CI	=	confidence	interval	
1Adjusted	for	treatment	allocation,	age,	gender,	baseline	stratification	factors	(type	of	headache	and	geographical	locality),	baseline	health-related	
quality	of	life	(QALY	model)	and	baseline	costs	(cost	model)	
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